A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Conditions
- Well Differentiated Liposarcoma
- Dedifferentiated Liposarcoma
- Liposarcoma
- Myxoid Liposarcoma
- Round Cell Liposarcoma
- Myxoid Pleomorphic Liposarcoma
- Pleomorphic Liposarcoma
- Unresectable Liposarcoma
- Unresectable Dedifferentiated Liposarcoma
Interventions
- DRUG: Mirdametinib
- DRUG: Palbociclib
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators